CAR T-Cell Therapy a China
CAR T Cell far in China yana ci gaba sosai kuma yana da yuwuwar sauya maganin cutar kansa. Yanzu kasar Sin ta zama majagaba a cikin wannan masana'antu, sakamakon ingantaccen tsarin da take da shi, da kayayyakin aikin bincike, wadanda suka kara habaka ci gabanta.
Ana samun maganin CAR T Cell a China akan dala 40,000. Bugu da ƙari, yawan majinyata na kasar Sin yana ba da fa'ida ta musamman don aiwatarwa gwaji na asibiti da tattara bayanai.
Yunkurin da kasar Sin ke yi na yin tasiri a nan gaba daidai magani da kuma samar da sabon bege ga masu fama da cutar kansa a duk faɗin duniya yayin da CAR T-cell ke samun ci gaba.
Me Ya Sa CAR T Kwayoyin Farfadowar Kwayoyin cuta A China Na Musamman?
CAR T-cell far a kasar Sin wani gagarumin ci gaba ne a fannin maganin ciwon daji kuma ya bai wa marasa lafiya wadanda a baya ba su da zabin sabon fata. Wannan m far Ya yi fice a kasar Sin, inda sama da 700 ke gudana gwaji na asibiti suna binciko hanyoyin inganta ingancinsa da amincinsa.
Kasar Sin ta fito a matsayin majagaba a wannan fanni, inda ta nuna kwazo sosai ga binciken likitanci da kuma kula da marasa lafiya na gaba. Kimiyya a baya CAR T Ciwon ƙwayar cuta don ciwon daji a China ya ƙunshi gyara na majiyyaci na rigakafin sel don gane da kuma kai farmaki ga kwayoyin cutar daji. Ana samun wannan ta hanyar injiniyan kwayoyin halitta, inda kwayoyin T na majiyyaci ke sanye da na'urar karban antigen na chimeric (CAR) wanda ke da alaka da cutar kansa. sunadaran. Ana cire ƙwayoyin T daga majiyyaci, a canza su ta hanyar gado a cikin dakin gwaje-gwaje, sannan a mayar da su cikin jikin majiyyaci don kai hari. ciwon daji.
CAR T cell far for cancer in china has been effective in treating a variety of cancers, and continuing research continues to refine and broaden its applicability. With commercial applications such as Yescarta and Relma-cel, the future of CAR T-cell treatment in China is bright, with major market growth projected and domestic players making substantial breakthroughs. The journey from clinical trials to commercial applications reflects the dedication to advancing medical science for the benefit of cancer patients in China.
CAR T Ciwon Kwayoyin Jiki A China Ya Zarce Amurka A Maganin Ciwon Daji!
Ta yaya China ke Mallake Gwajin Na asibiti?
Ya zuwa watan Janairu na shekarar 2024, akwai gwaje-gwaje sama da 700 na asibiti a halin yanzu da ake ci gaba da yi a asibitoci daban-daban na kasar Sin, wadanda suka mai da hankali kan ci gaban maganin CAR T. Tun daga shekarar 2017 gwamnatin kasar Sin ta zuba jari mai tsoka a sararin samaniyar fasahar kere-kere, kuma sakamakon yana da yawa. Kasar Sin ta fito a matsayin cibiyar bincike kan cutar daji, musamman a fannin aikin jiyya na CAR-T don magance cutar kansa a kasar Sin. Wadannan nazarce-nazarce da manyan cibiyoyi suka yi, suna samun ci gaba sosai wajen magance nau'ikan cututtukan daji daban-daban. CAR T maganin cutar sankarar bargo a kasar Sin, CAR T Kwayoyin Farko don lymphoma da kuma tushen BCMA CAR T Cell far don Multi myeloma a China wasu manyan nau'ikan ne waɗanda ke samun ingantacciyar amsa a cikin gwaji.
Misali, Asibitin Ciwon daji na Jami'ar Peking da ke birnin Beijing, kasar Sin ya nuna kyakykyawan sakamako wajen magance cutar sankarar cutar sankarar lymphoblastic mai saurin dawowa ko juriya (ALL) tare da kwayoyin CAR-T, yana ba da hanyar rayuwa ga marasa lafiya masu iyakacin zabi.
Ba wai kawai a kan cutar kansar jini ba ne; Har ila yau, kasar Sin tana duban maganin tantanin halitta na CAR-T don maganin ciwace-ciwacen daji, wanda a baya yana da wuyar magani. Don shawo kan matsalolin da ke damun garkuwar jiki da ke cikin ciwace-ciwace, ana amfani da dabaru masu wayo don inganta tasirin ƙwayoyin CAR-T.
Hadin gwiwar kasa da kasa na taka muhimmiyar rawa wajen samun nasarar kasar Sin, tare da hadin gwiwar masu bincike na kasar Sin a duk duniya don yin musayar fasahohi. Wannan yunƙurin na iya yin juyin juya hali na CAR T a China, yana ba da madadin dacewa kuma mai tsada.
Menene Fannin Farkon CAR-T A Kasar Sin?
Yin amfani da jiyya na T-cell na chimeric antigen (CAR) a cikin maganin cututtukan hematological ya kasance mai tasiri sosai. Aikace-aikacen jiyya na T-cell na CAR ya girma a China cikin shekaru tara da suka gabata.
Nazarin asibiti na farko na CAR T ya fara ne a cikin 2013, kuma ta hanyar 2017 an sami ƙarin gwaji na asibiti na CAR T fiye da da. Ba da dadewa ba, kasar Sin ta sanar da cewa, za ta samar da dalar Amurka biliyan 237 wajen samar da kudade don gudanar da sana'o'in kula da aikin jiyya a shekarar 2021, wanda ya nuna karuwar yawan gwaje-gwajen asibiti da muhimman ayyukan bincike da suka shafi kwayoyin CAR T.
Tallafin gwamnati mai karfi, shigar kudi, yawan bukatar marasa lafiya, tsarin kiwon lafiya na musamman, da kokarin likitoci da masana kimiyya na kasar Sin duk sun ba da gudummawa ga wannan gagarumin ci gaba da aka samu a kasar Sin.
CAR T-Cell tsarin jiyya
CAR T Cell Therapy for multiple myeloma in China, kazalika da sauran nau'in ciwon daji na jini, wani nau'i ne na ci-gaba na rigakafi wanda ya haɗa da sake tsara ƙwayoyin rigakafi na majiyyaci don ƙaddamarwa da kawar da kwayoyin cutar kansa. Tsarin tantanin halitta na CAR T ya ƙunshi matakai masu mahimmanci da yawa:
Tarin Kwayoyin Halitta (Apheresis):
Al'adar tattara ƙwayoyin T na majiyyaci, nau'in tantanin halitta na rigakafi, an san shi da apheresis. A lokacin apheresis, ana tattara jini daga majiyyaci kuma injin yana raba ƙwayoyin T. Sai a mayar da sauran jinin a jikin majiyyaci. Ana tattara ƙwayoyin T daga jini ta amfani da bututu da aka saka a cikin jijiya ta hannu. Wannan yana ɗaukar sa'o'i biyu.
Gyaran Halitta:
Kwayoyin T ana gyaggyarawa ta kwayoyin halitta a cikin dakin gwaje-gwaje don bayyana Chimeric Antigen Receptor (CAR) a saman su. An tsara CAR don gane takamaiman sunadaran, ko antigens, da ake samu a saman ƙwayoyin cutar kansa.
Fadada Sel:
Sannan ana haɓaka ƙwayoyin halittar T da aka gyara kuma ana haɓaka su, wanda ke haifar da ɗimbin adadin ƙwayoyin CAR T. Wannan hanya tana tabbatar da cewa akwai isassun ƙwayoyin sel T da aka gyaggyarawa don samun ingantaccen magani.
Yanayi (Lymphodepletion):
Marasa lafiya yawanci ana fuskantar maganin kwantar da hankali kafin jikowar tantanin halitta na CAR T, wanda zai iya haɗawa da ƙarancin maganin chemotherapy ko radiation. Wannan kwandishan yana taimakawa ƙirƙirar yanayi wanda sabbin ƙwayoyin CAR T zasu iya ninka kuma suyi aiki a cikin jikin majiyyaci.
Jiko na CAR T-Cells:
Da zarar an shirya, ana mayar da ƙwayoyin CAR T cikin jinin majiyyaci ta ɗigon ruwa. Kwayoyin CAR T da aka cusa sannan suna yawo cikin jiki, suna nema da ɗaure ga ƙwayoyin kansa waɗanda ke bayyana antigen da aka yi niyya.
Yin Niyya da Kashe Kwayoyin Cancer:
Lokacin da tantanin CAR T ya haɗu da kwayar cutar kansa mai ɗauke da antigen da ya dace, yana ɗaure ga ƙwayar cutar kansa. Wannan hulɗar tana kunna tantanin CAR T, yana haifar da sakin kwayoyin da ke kashe kwayar cutar kansa.
Kula da martani:
Ana kula da marasa lafiya sosai don kowane alamun amsawa, gami da raguwar girman ciwace-ciwacen daji. Ana kimanta nasarar maganin CAR T-cell ta amfani da nau'ikan hoto da gwajin gwaji.
Gudanar da Tasirin Side:
Wasu marasa lafiya na iya samun ciwon saki na cytokine (CRS) ko neurotoxicity, waɗanda kwararrun kiwon lafiya ke kulawa sosai.
Yadda ake Neman CAR T-Cell Therapy A China?
Aika rahotonku
Aika rahotanni masu zuwa waɗanda suka haɗa da taƙaitawar Likita, Sabbin rahotannin jini, Biopsy, Sabon PET Scan, Biopsy Marrow Biopsy (Idan akwai) zuwa info@cancerfax.com ko WhatsApp su a +1-213 789-56-55
Kima & Ra'ayi
Da zarar ƙungiyarmu ta karɓi rahoton ku na likitanci, muna bincika su kuma mu tura su asibitocin da ke yin maganin CAR T-Cell tare da irin wannan nau'in ciwon daji da alamar. Muna aika rahotanni zuwa ga kwararrun da abin ya shafa kuma mu sami ra'ayinsa. Muna kuma samun kiyasi daga asibiti kan cikakken magani.
Visa na likita da tafiya
Da zarar ka yanke shawarar ziyartar magani, mun shirya wasiƙar takardar visa ta likita da sauran takaddun da suka dace daga asibiti. Da zarar an shirya biza za mu taimaka da shiryar da ku don shirya tikitin tafiya da jirgin sama.
Jiyya da bibiya
Wakilinmu zai shirya wa likita alƙawari kuma ya cika muku ƙa'idodin rajista da suka dace. Zai kuma taimaka muku da shigar da ku a asibiti da sauran taimako da tallafi na gida da ake buƙata. Bayan an gama jinyar za mu shirya shawarwarin ku tare da likitan da ke jinya.
Me yasa kasar Sin ce mafi kyawun zaɓi?
Gwaje-gwaje na Clinical & Ci gaba Bincike
Tare da gwaje-gwajen asibiti sama da 700 da ake ci gaba da yi kan maganin CAR T-cell don cutar kansa a kasar Sin ya samu babban ci gaba. Masu bincike da cibiyoyin kiwon lafiya na kasar Sin sun haɓaka tare da gwada sabbin hanyoyin kwantar da hankali na CAR T-cell, tare da mai da hankali kan duka ciwace-ciwacen ciwace-ciwace da cututtukan jini. Dangane da ci gaban aikin jiyya na CAR T, kasar Sin ta kasance cikin sahun gaba, kuma ana yin gwaje-gwaje na asibiti da yawa a can. Saboda haka, marasa lafiya da ke neman samun dama ga abubuwan da suka faru na baya-bayan nan a cikin maganin tantanin halitta na CAR T na iya samun China a matsayin wata hanya mai ban sha'awa.
Farashin Da Samuwar
Farashin CAR T-Cell a China ya ragu sosai fiye da na ƙasashe kamar Amurka, UK, Ostiraliya, Japan, Koriya, da Singapore. CAR T-Cell far a China na iya kashe dala 60,000 kawai. Kasar Sin tana da kwatankwacin yawan samun magungunan CAR T don cutar kansa a kasar Sin. Wataƙila za a sami ɗan gajeren lokacin jira na jiyya a yanzu da ƙarin wuraren kiwon lafiya a China sun sami izini na tsari don ba da magungunan CAR T. Bugu da ƙari, maganin ƙwayoyin cuta na CAR T yawanci ba su da tsada a China fiye da yadda ake yi a wasu wurare, kamar Amurka. Wannan kashi na iya zama mahimmanci musamman ga mutanen da ke neman zaɓin magani mai araha.
Kwarewa Da Kwarewa
Sakamakon shiga cikin gwaje-gwajen asibiti da yawa da kuma hanyoyin kwantar da hankali, kasar Sin ta samu gagarumin ilimi da gogewa wajen samar da maganin cutar sankarar jini ta CAR T a kasar Sin, kwararrun likitocin kasar Sin sun inganta iliminsu game da matsalolin da ke da alaka da maganin CAR T da kuma karfinsu sarrafa su don inganta sakamakon haƙuri. Kasar Sin tana ba da ingantaccen kiwon lafiya godiya ga dimbin majinyata, kayayyakin tallafi, da kuma ilimin da ta tattara a cikin maganin CAR T don cutar kansa a kasar Sin.
Kamfanoni A Amurka Suna Haɗin Kai Da Kamfanonin China
A cikin 'yan shekarun nan, 'yan kasuwa na Amurka sun fara hada kai da takwarorinsu na kasar Sin don samar da magungunan CAR T. Don misali. A shekarar 2015, WuXi AppTec, wata kungiyar bincike ta kwangiloli ta kasar Sin (CRO), da Juno Therapeutics, wata masana'antar sarrafa magunguna ta Amurka, sun yi hadin gwiwa bisa dabara. Kamfanin Cellular Biomedicine Group na kasar Sin ya yi aiki tare da kamfanin Amurka Celgene, wanda a yanzu yanki ne na Bristol-Myers. Squibb. An yi haɗin gwiwa na duniya da yarjejeniyar lasisi tsakanin Janssen Biotech, wani kamfanin harhada magunguna mallakin Johnson & Johnson, da Legend Biotech, wani kamfani mai gudanar da ayyuka a China da Amurka.
Manyan Likitoci Don Maganin CAR-T A China
Ɗauki ra'ayi na biyu na ƙwararru kan jiko na CAR T-Cell daga mafi kyawun masu bincike a China.
Farfesa Peihua Peggy Lu, (MD)
Shugaban Babban Likita na Asibitin Lu Daopei, Beijing, China , Kwarewa: Shekaru 27
Dr Zhao Defeng (MD)
Darakta, Sashen Nazarin Jiki, Asibitin Gobroad na Beijing, Kwarewa: Shekaru 24
Dr. Zhao Defeng shi ne Daraktan Sashen Nazarin Jini na Gaobo Medical (Hematology) Cibiyar Bincike ta Beijing, Asibitin Gaobo Boren na Beijing, wanda ya kware a fannin ilmin jini na gaba daya a Ward tara. Ya rike mukamin Mataimakin Babban Likita kuma yana da digiri na biyu a Jami'ar Kiwon Lafiya ta Soja ta Biyu. Dr. Defeng yana da kwarewa tare da marasa lafiya fiye da 1000 da ke gudanar da maganin CAR T-cell kuma yana da fiye da 23 na gwaji na asibiti a kan shi. An dauke shi a matsayin daya daga cikin mafi kyawun likitoci don maganin CAR T-cell a China.
Manyan Asibitoci Don Maganin CAR T A China
Asibitin Cancer na Jami'ar Peking
Sabuwar hanyar rigakafin rigakafi da aka fi sani da CAR T-cell therapy ta nuna alƙawarin na musamman a cikin maganin cututtuka iri-iri. Birnin Beijing, Asibitin Ciwon daji na Jami'ar Peking na kasar Sin ya zama jagora a duniya wajen bunkasa maganin CAR T-cell. Tare da taimakon ƙungiyar su da yawa, wanda ya ƙunshi likitocin oncologists, immunologists, and geneticists, keɓaɓɓen maganin kansa ya sami ci gaba sosai. Asibitin Ciwon daji na Jami'ar Peking ya sami sakamako mai ban mamaki a cikin marasa lafiya da ke da cututtukan jini ta hanyar canza ƙwayoyin T na marasa lafiya don bayyana masu karɓar antigen na chimeric (CARs). Wannan babban magani yana ba masu cutar kansa sabon bege yayin da suke juyin juya halin ilimin cututtukan daji da haɓaka ƙimar rayuwa.
Asibitin Gobroad Boren na Beijing
Shahararren ƙwararren yana da shekaru talatin na ƙwarewar asibiti da na gwaje-gwaje na ciki, tare da mai da hankali musamman kan fannin ilimin jini. Sashen yana ba da sabis na bincike da magani da yawa don cututtukan da ke shafar tsarin jini, irin su myeloma da yawa, cutar sankarar bargo, lymphoma, thalassaemia, rikicewar coagulation, da ciwace-ciwacen jini. Ya ƙware a cikin tsare-tsaren jiyya na mutum ɗaya da haɗaɗɗen ganewar asali don cututtukan hematologic. Zaɓuɓɓukan jiyya don ciwace-ciwacen jini sun haɗa da chemotherapy, immunotherapy, far da aka yi niyya, demethylation, da radiotherapy. Bugu da ƙari, don tabbatar da aminci da ingancin amfani da magunguna, ma'aikatan mu na likitanci suma suna canza allurai daidai da halaye na ƙwayoyin cuta na ƙwayar cuta da sa ido kan tattara magunguna.
Asibitin Lu-Daopei
Asibitin Lu Daopei na birnin Beijing, na kasar Sin, ya samu ci gaba sosai a fannin kula da kwayar cutar ta CAR. Asibitin Lu Daopei, wanda ke ba da fifiko kan maganin ciwon daji da bincike, ya kasance a kan gaba wajen yin amfani da maganin CAR T-cell don magance cututtukan jini. Kwararrun likitocin oncologists, likitocin rigakafi, da masana ilimin gado a cikin ƙungiyarsu sun himmatu don kammala gwaje-gwajen asibiti da ƙirƙirar takamaiman maganin CAR T-cell na haƙuri. Asibitin Lu Daopei ya ga ci gaba mai ƙarfafawa a cikin sakamakon marasa lafiya da ƙimar rayuwa saboda iliminsa da manyan wuraren aiki. Ayyukan su na ci gaba da tasiri yadda ake magance ciwon daji, yana buɗe sabon dama ga marasa lafiya waɗanda ke buƙatar bege. Ya zuwa yau, suna da'awar sun yi fiye da 1000 CAR T-Cell jiko na far.
Asibitin Haɗin Kan Farko, Makarantar Magunguna ta Jami'ar Zhejiang, Hangzhou
Asibitin Farko na Farko, Makarantar Magunguna ta Jami'ar Zhejiang an kafa shi a cikin 1947. Shi ne asibitin farko na Jami'ar Zhejiang, rukunin farko na Cibiyoyin da za su gina cibiyoyin kula da lafiya na "mafi-girma" na kasa, Cibiyar Kula da Lafiya ta Kasa don Cututtuka, Cibiyar Jagoranci. Abubuwan da aka bayar na Constructing National-Level Co
Asibitin Haɗin Kan Farko, gidan yanar gizon Makarantar Magunguna na Jami'ar Zhejiang
Asibitin Haɗin Kan Farko Na Jami'ar Zhengzhou
A fannin maganin CAR T-cell, asibitin farko na jami'ar Zhengzhou dake birnin Zhengzhou na kasar Sin, ya zama sanannen kungiya. Asibitin ya sami babban ci gaba wajen haɓaka yuwuwar maganin CAR T-cell ga marasa lafiya ta hanyar ba da fifiko kan manyan hanyoyin magance cutar kansa. Likitocin Oncologists, Immunologists, Geneticists, da sauran membobi na ma’aikatan aikin jinya na tsaka-tsakinsu duk sun dauki rawar gani a cikin karatu da gwaje-gwajen asibiti. Ginin ya yi maganin cututtukan jini tare da nasara mai ban sha'awa godiya ga amfani da CAR T-cell far. Yayin da ake ci gaba da bunƙasa maganin kansar kansa, Asibitin Farko mai alaƙa na Jami'ar Zhengzhou yana kan gaba, yana ba marasa lafiya sabon fata da ingantacciyar rayuwa.
Farashin CAR T-Cell a China
Bari mu yi la'akari a kusa da farashin CAR-T tantanin halitta a kasar Sin. Yana yawanci jeri daga $45,000 zuwa $80,000. Farashin FUCASO (CAR T-Cell na tushen BCMA don maganin myeloma da yawa) yana kusan $ 200,000 USD. Amma ka tuna cewa waɗannan ƙididdigewa ne kawai, kuma ainihin farashin ya dogara da wasu dalilai. Nau'in maganin CAR-T, rikitarwar magani, kuɗin asibiti, ƙarin kulawa, da bincike na iya shafar ƙimar ƙarshe. Ka tuna cewa waɗannan lambobin zasu iya canzawa bisa yanayin lafiyar ku. Don taimakawa sarrafa waɗannan farashin, dole ne ku tuntubi ƙungiyar kula da lafiyar ku. Za su iya ba ku ƙarin keɓaɓɓen bayani. Hakanan yakamata ku bincika don ganin ko inshorar ku ya rufe shi ko kuma akwai wasu shirye-shiryen taimakon kuɗi. Wannan yana ba ku damar yanke shawara mafi kyau don maganin ku da kasafin kuɗi.
Menene CAR T-Cell Far?
Chimeric antigen receptor T-cell far, wanda aka fi sani da CAR T-cell therapy, wani maganin rigakafi ne mai rushe ƙasa wanda ya canza gaba ɗaya yadda ake bi da ciwon daji. Yana ba wa marasa lafiya da wasu cututtukan daji fata waɗanda aka gani a baya a matsayin ba za a iya warkewa ba ko kuma suna da ƴan hanyoyin warkewa.
Maganin ya haɗa da yin amfani da ƙwayoyin rigakafi na majiyyaci-musamman, ƙwayoyin T-da kuma gyara su don inganta ƙarfin su don ganowa da lalata ƙwayoyin cutar kansa. Don yin wannan, ana ba da ƙwayoyin T na ƙwayoyin cuta na chimeric antigen receptor (CAR), wanda ke ba su ikon kai hari kan wasu sunadaran sunadaran, ko antigens, a saman ƙwayoyin cutar kansa.
An fara cire ƙwayoyin T daga majiyyaci, sannan a canza su ta hanyar kwayoyin halitta don bayyana CAR. A cikin dakin gwaje-gwaje, waɗannan sel da aka canza suna haɓaka don samar da adadi mai yawa na ƙwayoyin CAR T, sannan a mayar da su cikin jinin mara lafiya.
Da zarar sun shiga cikin jiki, ƙwayoyin CAR T suna samun ƙwayoyin kansa waɗanda ke bayyana antigen da ake so, suna manne musu, kuma suna haifar da amsawar rigakafi. Kwayoyin CAR T da aka kunna suna yaduwa kuma suna kai hari kan ƙwayoyin cutar kansa, suna kashe su.
Ta yaya CAR T-Cell Therapy Aiki?
Lokacin da aka yi amfani da shi don magance wasu cututtuka na jini kamar m lymphoblastic cutar sankarar bargo (ALL) da takamaiman nau'i na lymphoma, CAR T cell far don lymphoma a china ya nuna sakamako na musamman. Ya haifar da ƙima mai ƙima da kuma a wasu marasa lafiya, har ma da dawwamammen gafara.
CAR T-cell far, duk da haka, hanya ce mai ƙwarewa kuma ta musamman wacce za ta iya samun haɗari da illa. Cytokine saki ciwo (CRS), wani tartsatsi na rigakafi dauki wanda zai iya haifar da mura-kamar bayyanar cututtuka da kuma, a cikin matsananci yanayi, gabobin jiki gazawar, na iya dandana daga wasu mutane. Haka kuma an sami rahotanni game da illar cutar jijiya, duk da haka ana iya warkewa akai-akai.
Duk da waɗannan matsalolin, CAR T-cell far wani gagarumin ci gaba ne a cikin yaƙi da ciwon daji kuma yana nuna babban damar nan gaba. Binciken na yanzu yana mai da hankali kan haɓaka ingancinsa da bayanin martabarsa tare da faɗaɗa amfaninsa zuwa nau'ikan ciwon daji daban-daban. CAR T-cell far na iya canza fuskar maganin cutar kansa kuma ya ba marasa lafiya a ko'ina sabon bege tare da ƙarin ci gaba.
Irin wannan jiyya ya ƙunshi gyaggyarawa ƙwayoyin T na majiyyaci, nau'in ƙwayoyin rigakafi, a cikin dakin gwaje-gwaje don su ɗaure su kashe ƙwayoyin cutar kansa. Wani bututu yana jigilar jini daga wata jijiya a hannun majiyyaci zuwa na'urar apheresis (ba a nuna ba), wacce ke fitar da fararen jini, gami da ƙwayoyin T, kuma ta mayar da sauran jinin ga majiyyaci.
Sa'an nan kuma ana gyare-gyaren kwayoyin halittar T sel a cikin dakin gwaje-gwaje don ƙunsar kwayar halitta don mai karɓa na musamman wanda aka sani da mai karɓar antigen na chimeric (CAR). Kwayoyin CAR T suna ninka a cikin dakin gwaje-gwaje kafin a shigar da su cikin majiyyaci da yawa. Kwayoyin CAR T za su iya gane antigen da ke kan sel masu ciwon daji, wanda ke kashe kwayoyin cutar kansa.
Wani nau'in Ciwon daji Za'a Iya Magancewa Tare da CAR-T Cell Therapy?
Sai kawai marasa lafiya da balagaggu B-cell wanda ba lymphoma Hodgkin ko yara masu cutar sankarar lymphoblastic na yara waɗanda suka riga sun gwada jiyya na al'ada guda biyu waɗanda ba su yi nasara ba a halin yanzu suna iya amfani da samfuran CAR T-cell waɗanda suka sami amincewar FDA. Duk da haka, an gwada maganin CAR T-cell a cikin nazarin asibiti a matsayin magani na farko ko na biyu don maganin lymphoma balagagge da kuma ciwon sankarar mahaifa mai tsanani na lymphoblastic na yara. Kwanan nan, wasu daga cikin binciken sun nuna nasarori masu ban mamaki a lokuta masu ƙarfi kamar glioblastoma, gliomas, ciwon hanta, ciwon huhu, ciwon GI, ciwon daji na pancreatic, da ciwon daji na baki.
Wannan yana wakiltar ci gaba mai mahimmanci a cikin kula da cutar sankarar bargo da B-cell lymphoma. Bugu da ƙari, yana ba da bege ga waɗanda aka yi hasashen rayuwarsu za ta wuce watanni shida kacal. Yanzu da muka gano hanyoyin juriya kuma mun ƙirƙiri ƙarin dabaru don yaƙar su, nan gaba yana da alama ya fi dacewa.
Tuntuɓi ƙwararrun ƙwararrun masu ba da lafiya a nan a Faxar Cancer don shawarwari na kyauta don tsara tsarin kulawa mai dacewa don bukatun ku na kiwon lafiya. Da fatan za a aiko da rahoton likitan ku zuwa info@cancerfax.com ko WhatsApp a + 1 213 789 56 55.
Menene Fa'idodin CAR-T Salon Farko?
Babban fa'idar ita ce maganin CAR T-cell yana buƙatar jiko ɗaya kawai kuma galibi yana buƙatar makonni biyu na kulawar marasa lafiya. Marasa lafiya da lymphoma ba Hodgkin da cutar sankarar yara waɗanda aka riga aka gano, a gefe guda, yawanci suna buƙata. chemotherapy akalla watanni shida ko fiye.
Amfanin CAR T-cell far, wanda shine magani mai rai, na iya dawwama shekaru da yawa. Idan kuma lokacin da sake dawowa ya faru, ƙwayoyin za su iya ganowa da kuma kai hari ga ƙwayoyin cutar kansa saboda suna iya rayuwa a cikin jiki na tsawon lokaci.
Kodayake bayanin yana ci gaba, kashi 42 cikin 19 na marasa lafiya na lymphoma manya waɗanda suka yi amfani da CD15 CAR T-cell magani har yanzu suna cikin gafara bayan watanni XNUMX. Kuma bayan watanni shida, kashi biyu bisa uku na marasa lafiya da ke fama da cutar sankarar mahaifa mai tsanani na lymphoblastic na yara har yanzu suna cikin gafara. Abin takaici, waɗannan majiyyatan suna da ciwace-ciwacen ciwace-ciwacen daji waɗanda ba a samu nasarar yi musu magani ta amfani da ƙa'idodin kulawa na gargajiya ba.
Wane Irin Marasa lafiya Ne Zasu Kasance Masu Samun Nagartaccen Maganin CAR-T?
Marasa lafiya tsakanin shekaru 3 zuwa shekaru 70 sun gwada maganin CAR T-Cell don nau'ikan cututtukan daji na jini daban-daban kuma an same shi da tasiri sosai. Cibiyoyi da yawa sun yi iƙirarin ƙimar nasara fiye da 80%. Mafi kyawun ɗan takarar don CAR T-cell far a wannan lokacin shine ƙaramin yaro tare da cutar sankarar lymphoblastic mai tsanani ko kuma balagagge tare da lymphoma mai tsanani na B-cell wanda ya riga ya sami layi biyu na rashin tasiri.
Kafin ƙarshen 2017, babu wani tsarin kulawa da aka yarda da shi ga marasa lafiya waɗanda suka riga sun shiga cikin layi biyu na jiyya ba tare da samun gafara ba. Magani kawai da FDA ta amince da shi wanda ya zuwa yanzu ya tabbatar da cewa yana da fa'ida sosai ga waɗannan marasa lafiya shine CAR T-cell far.
Yaya Tasirin CAR-T Magungunan Kwayoyin cuta?
CAR T-cell far ya kasance mai tasiri sosai wajen magance wasu nau'in ciwon daji na jini, kamar cutar sankarar bargo na lymphoblastic (ALL) da lymphoma ba Hodgkin. A cikin gwaje-gwaje na asibiti, ƙimar amsawar sun kasance da kyau sosai, kuma yawancin marasa lafiya sun shiga cikin cikakkiyar gafara. A wasu lokuta, mutanen da suka gwada kowane magani sun sami gafara na dindindin ko ma yiwuwar warkewa.
Ɗaya daga cikin mafi kyawun abubuwa game da maganin CAR T-cell shine cewa yana kai hari ga ƙwayoyin da suka dace. Masu karɓar CAR waɗanda aka ƙara zuwa ƙwayoyin T suna iya samun takamaiman alamomi akan ƙwayoyin cutar kansa. Wannan yana ba da damar ba da magani da aka yi niyya. Wannan hanyar da aka yi niyya tana cutar da ƙwayoyin lafiya kaɗan gwargwadon yuwuwa kuma tana rage haɗarin illolin da ke zuwa tare da jiyya na gargajiya kamar chemotherapy.
Amma yana da mahimmanci a tuna cewa CAR T-cell far har yanzu wani sabon yanki ne wanda har yanzu yana canzawa. Masu bincike da likitoci suna aiki tuƙuru don magance matsaloli kamar tsadar tsada, yuwuwar sakamako mai tsanani, da gaskiyar cewa yana aiki ne kawai ga wasu nau'ikan cutar kansa.
A ƙarshe, CAR T cell far ga Multi myeloma a china ya nuna ya zama mai nasara sosai hanyar magance wannan ciwon daji. Ko da yake hanya ce mai ban sha'awa da ƙarfi, ana buƙatar ƙarin nazari da gwaje-gwaje na asibiti don inganta shi da kuma nemo sababbin hanyoyin amfani da shi. CAR T-cell far na iya canza yadda ake bi da kansa kuma ya sa abubuwa su zama mafi kyau ga mutane a duk faɗin duniya idan ta ci gaba da samun gyaruwa.
Ma'auni na Haɗa don CAR T-Cell Far:
- Marasa lafiya tare da CD19+ B-cell Lymphoma (Aƙalla 2 kafin hadewar chemotherapy)
- Don zama shekaru 3 zuwa 75
- Makin ECOG ≤2
- Mata masu yuwuwar haifuwa dole ne su sami fitsari cikigwajin da aka yi kuma an tabbatar da rashin lafiya kafin magani. Duk marasa lafiya sun yarda su yi amfani da amintattun hanyoyin hana haifuwa yayin lokacin gwaji kuma har sai an biyo baya na ƙarshe.
Sharuɗɗan Keɓe Don CAR T-Cell Far:
- Hawan jini na intracranial ko rashin sani
- Raunin numfashi
- Yaduwa coagulation na intravascular
- Hematosepsis ko kamuwa da cuta mara ƙarfi
- Ba a sarrafa shi ba ciwon sukari
CAR T-Cell Magungunan da USFDA Ta Amince
KYMRIAH
B-cell precursor m lymphoblastic cutar sankarar bargo, koma baya ko refractory yaduwa babban B-cell lymphoma
Cikakken ƙimar amsawa (CR):> 90%
Saukewa: CD19
Farashin: $ 475,000
Lokacin amincewa: Agusta 30, 2017
YASCARTA
Mai sake dawowa ko refractory yana yaduwa babban lymphoma na B-cell, relapsed ko refractory follicular cell lymphoma
Cikakkun martanin Cikakkun Amsa na Ciwon lymphoma ba Hodgkin (CR): 51%
Saukewa: CD19
Farashin: $ 373,000
Lokacin amincewa: Oktoba 2017, 18
TECARTUS
Maimaitawa ko mai jujjuyawa yana yaduwa babban lymphoma na B-cell
Cikakkar amsa ƙimar lymphoma na Mantle cell (CR): 67%
Saukewa: CD19
Farashin: $ 373,000
Lokacin da aka amince: Oktoba 18, 2017
BREYANZI
Maimaitawa ko mai jujjuyawa yana yaduwa babban lymphoma na B-cell
Cikakken ƙimar amsawa (CR): 54%
Saukewa: CD19
Farashin: $ 410,300
Lokacin da aka amince: Oktoba 18, 2017
ABECMA
Maimaitawa ko Mai Rarraba Multiple Myeloma
Cikakken ƙimar amsawa: 28%
Saukewa: CD19
Farashin: $ 419,500
An amince da shi: Oktoba 18, 2017
Menene Illolin Kwayoyin CAR-T?
A ƙasa akwai wasu illolin maganin CAR T-Cell.
- Ciwon saki na cytokine (CRS): Mafi rinjaye kuma mai yuwuwa gagarumin tasirin maganin CAR T-cell shine ciwon saki na cytokine (CRS). Alamu masu kama da mura, gami da zazzabi, gajiya, ciwon kai, da ciwon tsoka, ana kawo su ta hanyar gyare-gyaren ƙwayoyin T na cytokines. A cikin matsanancin yanayi, CRS na iya haifar da matsanancin zafin jiki, hauhawar jini, gazawar gabobin jiki, har ma da sakamako mai illa.
- Gubar Neurological: Wasu marasa lafiya na iya haifar da sakamako masu illa na jijiyoyi, wanda zai iya bambanta da tsanani daga ƙananan alamu kamar ruɗani mai sauƙi da rashin fahimta zuwa mafi tsanani kamar seizures, delirium, da encephalopathy. Bayan jiko na T-cell na CAR, yawan guba na jijiyoyin jiki yana faruwa akai-akai a cikin makon farko.
- Cytopenia: Maganin CAR T-cell zai iya haifar da ƙananan ƙwayoyin jini, irin su anemia (ƙananan ƙwayar jinin jini), neutropenia (ƙananan ƙwayar jinin jini), da kuma maganin ƙwaƙwalwar ƙwaƙwalwa (ƙananan adadin platelet). Cututtuka, zub da jini, da gajiyawa suna cikin haɗarin da waɗannan cytopenia za su iya tsananta.
- Cututtuka: CAR T-cell therapy's ƙwanƙwasa ƙwayoyin rigakafi masu lafiya yana ƙara haɗarin ƙwayoyin cuta, ƙwayoyin cuta, da fungal. Don hana kamuwa da cututtuka, ana iya buƙatar majiyyata a sa ido sosai kuma a ba su magunguna na rigakafi.
- Tumor Lysis Syndrome (TLS): Bayan CAR T-cell far, yana yiwuwa a wasu yanayi a iya sakin adadin abubuwan da ke cikin tantanin halitta zuwa cikin jini saboda saurin kashe ƙwayoyin tumor. Wannan na iya haifar da rashin daidaituwa na rayuwa, kamar yawan potassium, uric acid, da matakan phosphate, wanda zai iya lalata kodan kuma ya haifar da wasu matsaloli.
- Hypogammaglobulinemia: Maganin CAR T-cell yana da yuwuwar rage ƙwayar ƙwayar cuta, wanda zai iya haifar da hypogammaglobulinemia. Wannan na iya sa kamuwa da cuta mai maimaitawa ya fi yuwuwa kuma yana kira don ci gaba da maye gurbin maganin rigakafi.
- Yawan Guba: CAR T-cell far yana da yuwuwar cutar da gabobin da yawa, gami da zuciya, huhu, hanta, da koda. Wannan na iya haifar da gwaje-gwajen aikin koda mara kyau, al'amuran numfashi, matsalolin zuciya, da gwajin aikin hanta mara kyau.
- Hemophagocytic lymphohistiocytosis (HLH): Cutar da ba kasafai ba amma mai yiwuwa mai saurin kisa da ake kira hemophagocytic lymphohistiocytosis (HLH) na iya tasowa a sakamakon maganin CAR T-cell. Ya haɗa da wuce gona da iri na ƙwayoyin rigakafi, wanda ke haifar da mummunar lalacewar gabobin da kumburi.
- Hypotension da Riƙewar Ruwa: Sakamakon cytokines da ƙwayoyin CAR T suka saki, wasu marasa lafiya na iya haifar da ƙananan hawan jini (hypotension) da riƙewar ruwa. Don magance waɗannan alamomin, ana iya buƙatar matakan tallafi gami da ruwan jijiya da magunguna.
- Malignancin Sakandare: Rahotanni na malignancies na biyu da ke fitowa bayan maganin CAR T-cell sun wanzu, duk da ƙarancinsu. A halin yanzu ana gudanar da bincike kan yuwuwar kamuwa da cutar ta biyu da kuma haɗari na dogon lokaci.
Yana da mahimmanci a tuna cewa ba kowane majiyyaci ne zai sami waɗannan illolin ba kuma matakin hankalin kowane mutum zai bambanta. Don ragewa da rage girman waɗannan yuwuwar illolin, ƙungiyar likitocin suna bincikar marasa lafiya sosai kafin, lokacin, da kuma bayan maganin CAR T-cell.
Lokaci
Bincika ƙasa jimlar firam ɗin lokacin da ake buƙata don kammala tsarin jiyya na CAR T-Cell. Koyaya, tsarin lokaci ya dogara da yawa akan nisan dakin gwaje-gwaje daga asibitin da ya shirya CARs.
- Jarabawa & gwaji: mako guda
- Pre-treatment & T-Cell Tarin: mako guda
- Shirye-shiryen T-Cell & dawowa: makonni biyu zuwa uku
- 1st Tasirin bincike: makonni uku
- 2nd Tasirin Bincike: makonni uku.
Jimlar lokacin: 10-12 Makonni
Ta yaya CancerFax zai iya Taimaka muku Samun CAR T Cell Therapy?
Idan ya zo ga zaɓin abokin tarayya mai kyau don tafiyar maganin kansa, CancerFax ya fito a matsayin hasken tallafi da ƙwarewa. Tare da gogewa da yawa wajen ba da maganin CAR T-cell, mun fahimci mahimmancin lafiyar ku da wajibcin samun kyakkyawar kulawa. Abin da ke ware CancerFax shine ƙungiyarmu na kwazo da ƙwararrun ƙwararrun kiwon lafiya waɗanda ke ba da fifikon jin daɗin ku yayin aikin jiyya.
Mun yi imani da keɓaɓɓen magani saboda mun gane cewa kowane majiyyaci na musamman ne kuma yana buƙatar kulawa ta musamman. An nuna sadaukarwar mu ga ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararru da haɗin gwiwa tare da asibitoci da yawa, tare da tabbatar da cewa kun sami mafi kyawun zaɓuɓɓukan da suka dace don buƙatun ku ba tare da sadaukar da inganci ba. A cikin shekaru goma da suka gabata, CancerFax ya kasance amintaccen jagora ga marasa lafiya daga ƙasashe sama da 8, kuma mun himmatu don ƙaddamar da wannan matakin kulawa da tallafi gare ku. Tuntuɓi yau don karɓar mafi kyawun CAR T Cell therapy a China.
CancerFax ya haɗu tare da manyan asibitocin ciwon daji da na jini a kasar Sin Waɗancan cibiyoyin da aka amince da su don gudanar da aikin jiyya na CAR T. Dangane da yanayin lafiyar majiyyaci da kuɗi da kuma kusancin inda zai nufa, muna ba da shawarar asibiti mafi dacewa.
Tambayoyin da
Wadanne nau'ikan ciwon daji ne suka cancanci maganin CAR T-Cell a China?
A kasar Sin, an yarda da maganin CAR T-cell da farko kuma ana amfani da shi don maganin cututtukan jini, irin su lymphoma, cutar sankarar bargo, da myeloma.
Duk da yake akwai wasu gwaje-gwaje na asibiti da kuma ƙoƙarin bincike na binciken maganin CAR T-cell don ciwon ciwace-ciwace, ci gaba a wannan yanki ya kasance a hankali idan aka kwatanta da cututtukan jini.
Dangane da bayanan da ke akwai, CAR T-cell therapy don ƙwaƙƙwaran ciwace-ciwace suna da kashi 9% kawai na jimillar jimillar jimillar jimillar CAR T-cell da ake haɓakawa a China.
Yaya tasirin CAR T Cell far a China yake idan aka kwatanta da madadin jiyya?
An kwatanta tasirin maganin antigen receptor T-cell (CAR-T) a kasar Sin da madadin jiyya ta hanyar gwaji da bincike da yawa na asibiti. Ya zuwa shekarar 2022, kasar Sin tana da adadi mafi girma na binciken asibiti na CAR-T fiye da Amurka, musamman a cikin cututtukan jini. Magungunan CAR-T guda biyu, axicabtagene ciloleucel (Yescarta) da relmacabtagene autoleucel (Carteyva), an amince da su a kasar Sin ta Hukumar Kula da Kayayyakin Kiwon Lafiya ta Kasa (NMPA).
CAR-T far a kasar Sin ya nuna inganci a daban-daban na hematologic malignancies, ciki har da B-cell m lymphoblastic cutar sankarar bargo (ALL), lymphoma, da kuma mahara myeloma (MM). Koyaya, ƙalubalen sun kasance, kamar tsadar tsada, tsarin samarwa mai ɗaukar lokaci, da abubuwan da suka shafi rigakafi. Don magance waɗannan batutuwa, masu bincike na kasar Sin suna haɓaka dabarun inganta fasahar CAR-T, ciki har da haɓaka samfuran allogen CAR-T da kuma amfani da madadin wuraren kashe kuɗi.
A taƙaice, maganin CAR-T a kasar Sin ya nuna sakamako mai ban sha'awa a cikin cututtukan cututtukan jini, tare da adadi mai yawa na gwaji na asibiti idan aka kwatanta da Amurka. Duk da haka, ƙalubalen sun kasance, kuma ana buƙatar ƙarin bincike don inganta farfadowa da fadada amfani da shi zuwa ciwace-ciwacen ƙwayoyi.
Wadanne illolin da aka lura da su daga CAR T Cell therapy a China?
A kasar Sin, illolin da aka lura daga maganin CAR T-cell sun hada da:
- Ciwon Sakin Cytokine (CRS)
- Neurotoxicity ko abubuwan da ke faruwa na jijiyoyin jini
- Cututtuka, musamman cututtukan cututtuka
- Ragewar sel B (aplasia)
- Hypogammaglobulinemia
- Cytopenia
Waɗannan illolin ba su keɓanta ga China ba amma suna da yawa a duk faɗin CAR T-cell far a duk duniya. Gudanarwa da rigakafin waɗannan illolin suna da mahimmanci don tabbatar da amincin haƙuri da haɓaka sakamakon jiyya.
Yaya tsadar lafiyar CAR T a China?
Saye-shaye na jiyya na ƙwayoyin salula na CAR-T a cikin Sin gabaɗaya yana kusan Yuan na Sin (CNY) 1,200,000, wanda yayi daidai da kusan dalar Amurka 170,000. Tasirin farashi na CAR-T cell far a kasar Sin ya bambanta dangane da takamaiman magani da yanayin mai haƙuri. Misali, ƙimar ƙimar ƙimar haɓaka (ICER) don Axicabtagene ciloleucel (Axi-cel) tare da daidaitattun kulawa (SOC) ga marasa lafiya tare da babban ƙwayar lymphoma B-cell (DLBCL) a cikin saitin layi na biyu (2L) ya kasance kusan. CNY 363,977 a kowace shekarar rayuwa mai inganci (QALY). Koyaya, ba a ɗaukar waɗannan hanyoyin kwantar da hankali masu tsada a cikin kowane saiti na layi don marasa lafiya na DLBCL a Hukumar Lafiya ta Duniya (WHO) ta ba da shawarar yarda-da-biya. Rage farashin hanyoyin kwantar da hankali na CAR-T babbar hanya ce don rage ICERs da kuma tabbatar da cewa farashin magunguna ya yi daidai da fa'idodin lafiyar marasa lafiya.
Shin akwai gwaje-gwajen asibiti da ke gudana don maganin CAR-T a China?
Ee, ana ci gaba da gwaje-gwajen asibiti don maganin ƙwayoyin cuta na CAR-T a China. Ya zuwa Janairu 2024 akwai fiye da 700 da ke gudana na gwaji na asibiti don CAR T Cell therapy a China. Kasar Sin ta zama kasar da ta fi yin rajistar gwajin CAR-T, kuma wannan yanayin ya ci gaba tun daga lokacin. Gwamnatin kasar Sin ta zuba jari mai tsoka a fannin binciken CAR-T, kuma kasar tana da dimbin gwaje-gwaje na asibiti da bincike na asali a wannan fanni. Waɗannan gwaje-gwajen sun ƙaddamar da iyakokin jiyya daga cututtukan hematologic zuwa ciwace-ciwacen ƙwayar cuta da wasu cututtuka ma.
Ta yaya zan sami mafi kyawun asibiti ko likita wanda ke ba da maganin CAR T-cell a China?
CancerFax ya fahimci mahimmancin zabar mafi kyawun kayan aiki da ƙwararrun magungunan CAR T a China. Sabis ɗinmu mai sadaukarwa yana mai da hankali kan haɗa mutane tare da mafi kyawun kula da kansa akan farashi mai araha. Muna aiki musamman tare da manyan ƙwararrun asibitocin ilimin jini da ciwon daji a China waɗanda suka sami izini don gudanar da maganin ƙwayar cuta ta CAR T. Muna taimaka wa marasa lafiya su zaɓi mafi kyawun zaɓi kamar buƙatun su da buƙatun su.
Menene buƙatun don la'akari da cancantar CAR T-CELL magani a China?
Bukatun cancanta don maganin CAR T cell far a China sun bambanta dangane da takamaiman jiyya da yanayin mai haƙuri. Gabaɗaya, marasa lafiya da ke da cututtukan jini, irin su lymphoma, cutar sankarar bargo, da myeloma, sune manyan ƴan takara don maganin ƙwayar cuta ta CAR T a China.
Dole ne majiyyata sun tabbatar da ganewar asali na takamaiman nau'in ciwon daji kuma sun kasa amsa daidaitattun jiyya, kamar chemotherapy ko radiation far.
Bugu da ƙari, dole ne majiyyata su cika wasu sharuɗɗan kiwon lafiya, kamar samun isassun aikin gabobin jiki da rashin samun kamuwa da cuta ko wasu munanan yanayin likita waɗanda zasu iya tsoma baki tare da jiyya. Ma'auni na cancanta ga kowane gwaji na asibiti na iya bambanta, kuma dole ne marasa lafiya su cika takamaiman buƙatun gwajin don shiga.
Don a yi la'akari da cancantar maganin CAR T cell far a kasar Sin, marasa lafiya dole ne su cika wasu sharudda. Waɗannan sharuɗɗan sun haɗa da CD19+ B-cell Lymphoma tare da aƙalla zaman haɗin chemotherapy biyu na farko, kewayon shekaru 3 zuwa 75, da ƙimar ECOG na ≤2. Bugu da ƙari, ga mata marasa lafiya na iya haifuwa, dole ne a yi gwajin ciki na fitsari da kuma tabbatar da mummunan kafin a fara farfasa. Bugu da ƙari kuma, duk marasa lafiya dole ne su yarda su yi amfani da ingantaccen hanyar hana haifuwa yayin gwajin kuma har sai an biyo baya.
Shin akwai wasu dokoki ko ƙuntatawa ga marasa lafiya na ƙasashen waje da ke tafiya zuwa China don karɓar magani tare da maganin ƙwayar cuta ta CAR T?
Babu irin wannan ƙuntatawa ga marasa lafiya na kasashen waje. Koyaya, samun kyakkyawan magani a China yana buƙatar samun izini daga hukumomin kiwon lafiya da takardar izinin likita.
Har yaushe za mu iya tsammanin ganin sakamako daga Motar T-Cell jiyya A China?
Ƙayyadaddun lokaci don marasa lafiya don ganin sakamako daga CAR T cell far a China na iya bambanta. Yawancin lokaci, ana yin sikanin bayan makonni 2-3 don bincika tasirin maganin CAR T. Magungunan ƙwayoyin cuta na CAR T sun sami gagarumar nasara wajen magance cututtukan jini, kuma kasar Sin ta zama babbar ƙasa a gwajin asibiti na CAR T. Duk da haka, yana da mahimmanci a lura cewa sakamakon CAR T cell far zai iya bambanta ga kowane majiyyaci, kuma ƙayyadaddun lokaci don ganin sakamakon zai iya dogara da dalilai kamar yanayin mai haƙuri, nau'in ciwon daji da ake bi da shi, da kuma takamaiman CAR T. ana amfani da maganin tantanin halitta. Duk da yake maganin ya nuna sakamako mai ban mamaki na asibiti, ciki har da ƙimar amsawa gabaɗaya, ainihin lokacin lokacin da mai haƙuri zai iya tsammanin ganin sakamakon bazai iya bayyana a duniya ba kuma zai iya bambanta daga mutum zuwa mutum. Sabili da haka, ana ba da shawarar marasa lafiya su tuntuɓi masu ba da lafiyar su da masu binciken gwaji na asibiti don takamaiman bayani game da lokacin da ake tsammani don ganin sakamako daga magungunan CAR T.
Shin ana buƙatar kulawa na dogon lokaci ko kulawa ga marasa lafiya waɗanda suka yi maganin CAR T-Cell a China?
Ee, ana buƙatar kulawa na dogon lokaci ko saka idanu ga marasa lafiya waɗanda suka sha maganin CAR T a China. CAR T cell far ya nuna na ban mamaki sakamako na asibiti a cikin lura da hematological malignancies, amma kuma yana iya samun m illa, kamar cytokine saki ciwo (CRS) da neurotoxicity.
Sabili da haka, marasa lafiya waɗanda suka yi amfani da maganin ƙwayar cuta ta CAR T suna buƙatar kulawa ta kusa don yiwuwar sakamako masu illa da kuma bin dogon lokaci don tantance ƙarfin amsawa da yiwuwar sake dawowa na ciwon daji. Tsawon lokacin bin diddigin na iya bambanta dangane da takamaiman magani da yanayin majiyyaci, amma yawanci ya haɗa da dubawa na yau da kullun da gwaje-gwajen hoto don lura da lafiyar majiyyaci da gano duk wani yiwuwar sake faruwa na cutar kansa.
Bugu da ƙari, marasa lafiya na iya buƙatar kulawar tallafi, kamar magunguna don sarrafa illa ko ƙarin jiyya idan ciwon daji ya sake dawowa.
Shin zai yiwu a haɗa magungunan CAR T tare da wasu jiyya kamar chemotherapy, radiation, ko dashen kasusuwa?
Ee, yana yiwuwa a haɗa maganin ƙwayar cuta ta CAR T tare da wasu jiyya kamar chemotherapy, radiation, ko dashen kasusuwa. Ana samun karuwar sha'awa wajen hada maganin CAR T tare da sauran magungunan maganin ciwon daji don inganta sakamakon jiyya, musamman ma a cikin mahallin ciwon jini. Misali, a cikin myeloma, haɗe-haɗe na iya haɗawa da daidaitaccen maganin myeloma da aka bayar bayan jiko T-cell na CAR azaman dabarun kulawa.
Bugu da ƙari, haɗe-haɗe na aikin rediyo tare da maganin ƙwayar cuta ta CAR-T ya nuna sakamako masu ban sha'awa wajen haɓaka takamaiman rigakafi da ƙirƙirar microenvironment mafi kyawun ƙwayar cuta don ƙwayoyin CAR-T a cikin ciwace-ciwace.
Bugu da ƙari kuma, an bincika haɗin ilimin chemotherapy tare da maganin ƙwayoyin cuta na CAR-T a matsayin dabarun shawo kan shinge a cikin maganin kwayoyin halitta na CAR-T da kuma samar da tasirin haɗin gwiwa, musamman ma a cikin maganin ciwace-ciwacen ƙwayoyi. Waɗannan hanyoyin haɗin gwiwar suna nufin haɓaka aminci da ingancin maganin ƙwayar cuta ta CAR-T ta hanyar gyaggyara microenvironment na ƙari, inganta tsarin CAR, da yuwuwar ƙaddamar da antigens da yawa.
Wane ci gaba ko ci gaba ke faruwa a cikin binciken CAR T-cell far a cikin Sin?
A kasar Sin, binciken binciken kwayar cutar CAR T yana tasowa cikin sauri, inda kasar ke da mafi yawan gwaje-gwajen asibiti na CAR T tun daga shekarar 2017. Gwamnatin kasar Sin ta ba da jari mai yawa a fannin maganin kwayar cutar ta CAR T, kuma kasar tana da adadi mai yawa na gwaje-gwaje na asibiti da na asali. bincike a wannan fanni. An yarda da magungunan CAR T don maganin cututtuka na hematological, irin su yaduwa babban lymphoma B-cell (DLBCL).
Masu bincike a kasar Sin suna binciko dabaru daban-daban don inganta fasahar tantanin halitta ta CAR T, gami da samar da sabbin hanyoyin gina CAR, hanyoyin kwantar da hankali tare da sauran jiyya, da kuma amfani da kwayoyin CAR T a cikin ciwace-ciwace. Koyaya, ƙalubalen sun kasance, kamar sarkar masana'anta da gudanarwa, tsadar magani, da buƙatar ƙarin ma'ana da gwaji na asibiti na asali.
Duk da katsewar gwaje-gwajen asibiti sakamakon cutar sankarau ta COVID-19, ana ci gaba da bincike a kasar Sin, tare da hukumar kula da kayayyakin kiwon lafiya ta kasar, wato NMPA, bayan da ta amince da na'urorin CAR T guda biyu kacal na sabbin bayanai da aka samu.
Wadanne matakai ne gaba daya ya shafi tafiya zuwa kasar Sin don maganin CAR-T-cell?
Gabaɗayan matakan da ke tattare da balaguro zuwa kasar Sin don maganin jiyya na ƙwayoyin cuta na CAR T na iya bambanta dangane da takamaiman asibiti ko cibiyar jiyya. Koyaya, wasu matakan gabaɗaya na iya haɗawa da:
1. Binciken asibitoci ko cibiyoyin kula da lafiya a kasar Sin wadanda ke ba da magungunan CAR T da zabar wanda ya dace da bukatun ku.
2. Tuntuɓar asibiti ko cibiyar kulawa don tambaya game da tsarin jiyya, gami da farashi, buƙatun cancanta, da kowane takaddun da suka dace.
3. Samun mai magana daga mai ba da lafiyar ku da bayar da bayanan likita zuwa asibiti ko cibiyar kulawa.
4. Neman takardar izinin likita don tafiya China don magani.
5. Shirya tafiye-tafiye da masauki don kanku da duk wani dangi mai rakiya.
6. Yin kima da gwaji na likita idan an isa asibiti ko cibiyar kula da lafiya.
7. Karɓar maganin CAR T cell far da kuma jurewa duk wani mahimmancin kulawa.
8. Komawa gida da ci gaba da kulawa da kulawa na dogon lokaci.
Yana da mahimmanci a lura cewa ƙayyadaddun matakan da ke tattare da tafiya zuwa kasar Sin don maganin jiyya na ƙwayoyin cuta na CAR T na iya bambanta dangane da asibiti ko cibiyar jiyya da yanayin daidaikun majiyyaci. Ana ba da shawarar marasa lafiya su tuntuɓi masu ba da lafiyar su da asibiti ko cibiyar kulawa don takamaiman bayani game da tsarin jiyya da buƙatun tafiya.
CancerFax yana kula da duk waɗannan matakan don ku ci gaba da mai da hankali kan jiyya yayin da muke kula da duk wasu abubuwa.
Menene nasarar CAR T a China?
CAR T-cell far ya nuna sakamako mai ban sha'awa a cikin maganin cutar kansar jini a China. Ya zuwa watan Janairu na shekarar 2024, kasar Sin ta sami mafi yawan gwaje-gwajen asibiti a duniya gwajin CAR T-cell far, inda 337 suka mai da hankali kan cutar kansar jini, yayin da 111 kan ciwace-ciwace. CAR T-cell far rage ciwace-ciwacen daji a cikin 75.9% na marasa lafiya na lymphoma wadanda cutar ta dawo bayan jiyya na baya sun kasa. Fiye da rabi (51.7%) na marasa lafiya ba su da ciwace-ciwacen da aka gano bayan jiyya. Bayan shekara guda, 76.8% na marasa lafiya na lymphoma sun kasance da rai. Kasar Sin ta amince da maganin CAR T-cell guda biyu masu suna FKC876 da Carteyva don maganin cutar kansa. Kasar Sin ce ke jagorantar bincike da ci gaba a duniya a fannin maganin CAR T-cell.